PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT DOCTRINE
CALDERWOOD & HARKNESS LLP 200 Park Avenue, 42nd Floor New York, New York 10166
MEMORANDUM
August 23, 2024
Matter No.: 1018-00008
To: Oliver Mackenzie, Partner, Mergers & Acquisitions
From: Megan Chu, Associate, Mergers & Acquisitions
Re: Impact of FDA Partial Clinical Hold on VRD-4187 (IND 154832) on Satisfaction of Buyer's Closing Conditions Under the Stock Purchase Agreement Dated June 10, 2024
Client: Penterra Pharmaceuticals Corp.
This memorandum is a privileged and confidential attorney-client communication and attorney work product. It is intended solely for the use of the addressee and those persons identified in the distribution list below. This memorandum contains legal analysis prepared in anticipation of litigation and for the purpose of rendering legal advice. It should not be disclosed to any third party without the prior written consent of Calderwood & Harkness LLP and the client.
I. Executive Summary
On August 22, 2024, the United States Food and Drug Administration ("FDA") imposed a partial clinical hold on VRD-4187 under Investigational New Drug Application No. 154832 ("IND 154832"). VRD-4187 is Veridian Biosciences, Inc.'s ("Veridian" or the "Company") lead immuno-oncology candidate — a bispecific T-cell engager targeting delta-like ligand 3 ("DLL3")-expressing tumors in patients with small cell lung cancer ("SCLC"). VRD-4187 is the Company's most advanced clinical-stage asset and the primary strategic rationale underlying Penterra Pharmaceuticals Corp.'s ("Penterra" or the "Buyer") proposed acquisition of Veridian pursuant to the Stock Purchase Agreement dated June 10, 2024 (the "SPA").
The partial clinical hold follows the August 14, 2024 interim analysis conducted by the independent Data Monitoring Committee ("DMC") for the Marlowe Asset Management-2 Phase II clinical trial (ClinicalTrials.gov Identifier: NCT05837291). The DMC's interim analysis revealed a statistically significant increase in serious adverse events in the VRD-4187 treatment arm relative to the control arm. Specifically, Grade 3 or higher cytokine release syndrome ("CRS") was observed at a rate of 23.4% in the treatment arm (45 of 194 patients) versus 4.1% in the control arm (8 of 193 patients) — a difference of 19.3 percentage points. More critically, the interim data disclosed seven treatment-related deaths in the VRD-4187 arm (3.6% of 194 patients) compared to one death in the control arm (0.5% of 193 patients). Meanwhile, the overall response rate ("ORR") for VRD-4187 was 31.4%, compared to 28.9% in the control arm, a difference that was not statistically significant (p = 0.58). In sum, the data suggest that VRD-4187 presents a materially worse safety profile than standard of care without offering a statistically significant efficacy advantage.
This memorandum analyzes the impact of the partial clinical hold on the satisfaction of the Buyer's closing conditions under Sections 7.2(a) and 7.2(b) of the SPA. We also briefly address the implications for Section 7.2(c) (covenant compliance) and Section 8.1(d) (termination rights). A comprehensive analysis of whether a material adverse effect ("MAE") has occurred within the meaning of SPA § 1.1 is the subject of a companion memorandum currently in preparation (expected delivery August 25–27, 2024), which will incorporate a detailed survey of Delaware MAE case law and a thorough carveout-by-carveout analysis.
Our preliminary conclusion is as follows: the partial clinical hold, in conjunction with the underlying Marlowe Asset Management-2 clinical data, presents a strong basis for Penterra to assert that the conditions to closing under SPA §§ 7.2(a) and 7.2(b) are not currently satisfied and may not be capable of satisfaction prior to the Outside Date of December 10, 2024. Accordingly, Penterra has a valid basis to deliver a formal Deficiency Notice under SPA § 8.1(d) and, if the conditions remain incapable of cure within the applicable cure period, to exercise its right to terminate the SPA. We recommend that Penterra take prompt steps to preserve its rights and options as described in Part VIII of this memorandum.
II. Background
A. The Transaction
On June 10, 2024, Penterra Pharmaceuticals Corp. (Nasdaq: PPCA), a Delaware corporation headquartered in Princeton, New Jersey, entered into the SPA to acquire 100% of the outstanding capital stock of Veridian Biosciences, Inc., a privately held Delaware corporation based in Cambridge, Massachusetts, for aggregate cash consideration of $900,000,000, subject to customary adjustments for net working capital, indebtedness, and transaction expenses (the "Transaction"). The SPA was negotiated over a period of approximately four months, with preliminary term sheet discussions commencing in January 2024 and exclusive negotiations beginning in March 2024.
Penterra is a publicly traded specialty pharmaceutical company with an approximate market capitalization of $14.2 billion as of the date of this memorandum. For the fiscal year ended December 31, 2023, Penterra reported total revenue of $4.87 billion and net income of $623 million. As of the end of the second quarter of 2024 (June 30, 2024), Penterra reported cash, cash equivalents, and marketable securities of approximately $2.1 billion. Penterra's commercial portfolio comprises twelve marketed products spanning oncology, immunology, and rare diseases, with its oncology franchise contributing approximately 41% of total revenue.
The strategic rationale for the Transaction was principally to bolster Penterra's immuno-oncology pipeline, which had been materially weakened following the failure of Penterra's lead internal immuno-oncology candidate, PPC-0921, after a Phase III futility analysis in November 2023. The loss of PPC-0921 created a significant gap in Penterra's oncology pipeline and was the subject of adverse analyst commentary and a approximately 12% decline in Penterra's share price in the weeks following the futility announcement. The acquisition of Veridian and its VeriTCE T-cell engager platform, anchored by VRD-4187, was intended to replenish that pipeline and signal to the market that Penterra had a viable path forward in immuno-oncology. As stated in Penterra's Current Report on Form 8-K filed June 11, 2024, the Transaction was expected to "transform Penterra's immuno-oncology portfolio and provide a differentiated late-stage clinical candidate with significant commercial potential."
Veridian Biosciences, Inc. is a clinical-stage biotechnology company founded in 2016 by Dr. Julian Marek and Dr. Priya Chandrasekaran, both formerly of the Dana-Farber Cancer Institute. Veridian is focused on developing immuno-oncology therapeutics leveraging its proprietary VeriTCE (Veridian T-Cell Engager) bispecific antibody platform. The Company has no product revenue. For the fiscal year ended December 31, 2023, Veridian reported total revenue of $0 and a net loss of approximately $87.3 million, funded primarily through venture capital investment. Since its founding, Veridian has raised approximately $420 million in equity financing through Series A through Series D preferred stock rounds.
The principal stockholders of Veridian are as follows:
Pursuant to the stockholder approval requirements of the SPA and Veridian's certificate of incorporation, Veridian's stockholders delivered an action by written consent approving the Transaction on June 14, 2024, with stockholders holding in excess of 90% of the outstanding voting power executing the written consent. David Ng, a Managing Director of Crestline Ventures, LP, was designated as the Stockholder Representative under the SPA to act on behalf of the Sellers with respect to post-closing matters, including indemnification claims and escrow releases.
The Sellers are represented by Zalcourt Archer & Cole LLP, with Rebecca Whitmore serving as lead transaction counsel. Veridian's regulatory and FDA matters are managed internally by Dr. Anne-Marie Fontaine, Vice President of Regulatory Affairs.
With respect to regulatory approvals, the parties filed the required pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act") on April 22, 2024. Early termination of the HSR waiting period was granted on May 20, 2024. Accordingly, the antitrust condition to closing set forth in SPA § 7.1(a) has been satisfied.
B. VRD-4187 and the Marlowe Asset Management-2 Trial
VRD-4187 is Veridian's lead drug candidate and its most advanced clinical-stage asset. It is a bispecific T-cell engager antibody constructed on the Company's proprietary VeriTCE platform, designed to simultaneously bind to DLL3 on the surface of tumor cells and CD3 on T cells, thereby redirecting the patient's immune system to recognize and destroy DLL3-expressing tumors. DLL3 is an inhibitory Notch ligand that is highly expressed on the surface of SCLC tumor cells and neuroendocrine tumors, making it an attractive target for directed immunotherapy.
SCLC is an aggressive, high-grade neuroendocrine carcinoma representing approximately 13% of all lung cancers. SCLC is characterized by rapid proliferation, early metastasis, and high initial sensitivity to chemotherapy followed by near-universal relapse. Five-year survival rates for extensive-stage SCLC remain below 5%, and there has been a relative paucity of meaningful therapeutic advances in the last two decades, making SCLC an area of significant unmet medical need. The clinical and commercial thesis underlying the acquisition of Veridian was premised substantially on the potential for VRD-4187 to become a differentiated treatment option for relapsed or refractory SCLC.
Marlowe Asset Management-2 (ClinicalTrials.gov Identifier: NCT05837291) is a randomized, open-label, multi-center Phase II clinical trial evaluating VRD-4187 as monotherapy versus investigator's choice of standard-of-care topotecan or lurbinectedin in patients with relapsed or refractory SCLC after at least one prior line of platinum-based chemotherapy. The trial is being conducted at 42 clinical sites across the United States and the European Union, and has enrolled a total of 387 patients, with 194 patients randomized to the VRD-4187 treatment arm and 193 patients randomized to the control arm. VRD-4187 is administered intravenously at a dose of 1.5 mg/kg on Days 1 and 15 of each 28-day cycle.
On August 14, 2024, the independent DMC for the Marlowe Asset Management-2 trial conducted a pre-specified interim analysis at the 50% event threshold. Based on its review of the accumulating safety and efficacy data, the DMC recommended the immediate suspension of enrollment in the trial and the implementation of dose modification protocols. The DMC's recommendation was based on the following key findings from the interim analysis:
(i) Grade ≥3 Cytokine Release Syndrome (CRS). CRS of Grade 3 or higher severity was observed in 23.4% of patients in the VRD-4187 treatment arm (45 of 194 patients), compared to 4.1% in the control arm (8 of 193 patients). This represents a difference of 19.3 percentage points in the incidence of severe CRS — an approximately 5.7-fold increase relative to the control arm. CRS is a known class effect of T-cell engager therapies; however, the rate observed in Marlowe Asset Management-2 significantly exceeds the rates observed in prior T-cell engager programs in oncology and substantially exceeds the rates reported in Veridian's Phase I dose-escalation study (Marlowe Asset Management-1), where Grade ≥3 CRS was reported at approximately 8% at the 1.5 mg/kg dose level.
(ii) Treatment-Related Deaths. There were seven treatment-related deaths in the VRD-4187 arm (3.6% of 194 patients), compared to one treatment-related death in the control arm (0.5% of 193 patients). Six of the seven deaths in the treatment arm were attributed to complications of severe CRS (including multi-organ failure and disseminated intravascular coagulation), and one was attributed to treatment-emergent immune-mediated hepatotoxicity.
(iii) Overall Response Rate (ORR). The ORR in the VRD-4187 arm was 31.4%, compared to 28.9% in the control arm. This difference of 2.5 percentage points was not statistically significant (p = 0.58, two-sided Fisher's exact test). At the time of the interim analysis, there was no meaningful separation between the treatment and control arms with respect to the co-primary efficacy endpoints.
Penterra received formal notice of the DMC findings from Veridian on August 16, 2024 — two calendar days after the DMC meeting — pursuant to the notification obligations set forth in SPA § 5.1(b). The notice was delivered by email from Dr. Anne-Marie Fontaine to Thomas F. Holbrook, Penterra's General Counsel, with a copy to this firm.
On August 19, 2024, Broadleaf Scientific Consulting LLC ("Broadleaf"), Penterra's independent clinical due diligence advisor, delivered a supplemental clinical assessment to Penterra. The Broadleaf assessment, authored by Dr. Raymond Kapoor, a former FDA reviewer in the Division of Oncology Products, confirmed the severity of the safety signal, characterized the CRS rate as "far exceeding acceptable thresholds for a second-line SCLC therapy," and concluded that the Marlowe Asset Management-2 interim data "call into serious question the viability of VRD-4187 at the 1.5 mg/kg dose level and, more broadly, the risk-benefit profile of the drug candidate in its current clinical development posture." Dr. Kapoor further noted that the absence of meaningful efficacy differentiation relative to standard of care was "particularly concerning when considered alongside the significantly elevated mortality signal."
C. The FDA Partial Clinical Hold
On August 22, 2024, the FDA imposed a partial clinical hold on VRD-4187 under IND 154832 pursuant to 21 C.F.R. § 312.42. The partial clinical hold was communicated to Veridian by telephone from the Office of Oncologic Diseases, Division of Oncology Products 1, followed by a written notification letter from the FDA. Penterra was advised of the hold by Veridian on the same date.
Under FDA regulations, a partial clinical hold is a regulatory action that restricts certain aspects of a clinical investigation while permitting other aspects to continue. In the case of the VRD-4187 partial clinical hold, the FDA has prohibited new patient enrollment in the Marlowe Asset Management-2 trial and has imposed restrictions on ongoing dosing of currently enrolled patients pending investigation of the CRS-related deaths observed in the trial. The FDA's letter cited concerns regarding "the unacceptable rate of Grade 3 and higher cytokine release syndrome and an unacceptable number of treatment-related fatalities" and stated that the hold would remain in effect until the sponsor provides "a satisfactory response demonstrating that subjects will not be exposed to an unreasonable and significant risk of illness or injury."
It is important to note that a partial clinical hold, while less severe than a full clinical hold (which would halt all clinical activities under the IND), is nevertheless an extraordinary regulatory action. The FDA imposes clinical holds only when it determines that subjects in a clinical investigation face an "unreasonable and significant risk of illness or injury." See 21 C.F.R. § 312.42(b)(1). The imposition of a clinical hold is the FDA's most direct form of intervention in the conduct of a clinical trial, short of withdrawal of the IND itself.
Veridian's Vice President of Regulatory Affairs, Dr. Anne-Marie Fontaine, has been in ongoing communication with the FDA regarding the hold. We understand from Veridian's counsel, Rebecca Whitmore of Zalcourt Archer & Cole LLP, that Veridian intends to respond to the hold within the 30-day response window prescribed by 21 C.F.R. § 312.42(e). Veridian has not yet publicly disclosed the specific timeline for responding to the hold or the specific requirements that the FDA has identified as conditions for lifting the hold.
We further understand that Veridian's clinical development team is preparing a protocol amendment, which would be designated Protocol v4.0, intended to address the safety concerns raised by the DMC and the FDA. Based on preliminary communications from Veridian, the protocol amendment is expected to include, among other things: (a) mandatory tocilizumab prophylaxis for all patients receiving VRD-4187 (tocilizumab is an anti-IL-6 receptor antibody approved for the treatment of CRS); and (b) a reduction of the VRD-4187 dose from 1.5 mg/kg to 0.75 mg/kg. As of the date of this memorandum, the protocol amendment has not been formally finalized or submitted to the FDA or to any institutional review boards ("IRBs").
III. Relevant SPA Provisions
We set forth below the SPA provisions most directly relevant to the analysis of the impact of the partial clinical hold on Penterra's closing conditions and termination rights.
A. Section 7.2 — Conditions to Buyer's Obligations to Close
Article VII of the SPA sets forth the conditions precedent to the obligations of the respective parties to consummate the closing. Section 7.2 specifically addresses the conditions that must be satisfied (or waived by the Buyer) for Penterra to be obligated to close the Transaction. Unless and until all conditions set forth in Section 7.2 are satisfied or waived, Penterra is under no obligation to consummate the acquisition. The key conditions implicated by the clinical hold are addressed in turn below.
1. Section 7.2(a) — Bring-Down of Representations and Warranties
Section 7.2(a) of the SPA provides, in relevant part:
"The representations and warranties of the Sellers set forth in Article III of this Agreement shall be true and correct (without giving effect to any qualifications as to 'materiality' or 'material adverse effect' contained therein, except where a representation or warranty is qualified by 'material adverse effect' in the definition of the applicable representation or warranty) in all respects as of the date of this Agreement and as of the Closing Date as if made on and as of the Closing Date (except that representations and warranties that are made as of a specific date shall be true and correct in all respects as of such date), except for any failure of such representations and warranties to be true and correct that, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect."
This is a standard "bring-down" condition. Its operative effect is that the Sellers' representations and warranties, which were made as of the signing date of June 10, 2024, must also be true and correct as of the Closing Date, as though remade on such date. For representations that are not individually qualified by a materiality or MAE standard within the text of the representation itself, the bring-down applies a global MAE qualifier — that is, inaccuracies are excused only if they have not had and would not reasonably be expected to have a Material Adverse Effect. For representations that are specifically qualified by "Material Adverse Effect" within their own text, that internal qualification is given effect.
The key representations subject to the bring-down analysis in this context include, without limitation: (a) the Sellers' representations regarding regulatory compliance (SPA § 3.14); (b) the Sellers' representations regarding the status, conduct, and results of the Company's clinical trials (SPA § 3.15); and (c) the Sellers' representations regarding the absence of material governmental orders or proceedings adversely affecting the Company's business (SPA § 3.9). Each of these representations will be analyzed in Part IV below.
2. Section 7.2(b) — No Material Adverse Effect
Section 7.2(b) of the SPA provides:
"Since the date of this Agreement, there shall not have occurred any Material Adverse Effect."
This is a standalone closing condition, separate and distinct from the bring-down of representations under § 7.2(a). Even if the bring-down condition were satisfied (or its failure waived), the no-MAE condition independently requires the absence of any MAE since the date of the SPA (June 10, 2024). The definition of "Material Adverse Effect" is set forth in SPA § 1.1 and is discussed in further detail in Part III.C below.
3. Section 7.2(c) — Compliance with Covenants
Section 7.2(c) of the SPA provides:
"The Company shall have complied in all material respects with its covenants and obligations under this Agreement required to be performed by the Company at or prior to the Closing."
The covenants most directly relevant to the present circumstances include the operating covenants set forth in SPA § 5.1, which require the Company to conduct its business in the ordinary course consistent with past practice between signing and closing, and the notification obligations set forth in SPA § 5.1(b), which require the Company to promptly notify the Buyer of certain material developments. These covenants are analyzed in Part VI below.
B. Section 8.1 — Termination Rights
Section 8.1 of the SPA sets forth the circumstances under which either party may terminate the SPA prior to closing. The termination provision most relevant to the present circumstances is Section 8.1(d), which provides:
"This Agreement may be terminated by Buyer by written notice to the Company and the Stockholder Representative if any of the conditions set forth in Section 7.2 shall have become incapable of being satisfied prior to the Outside Date; provided, however, that Buyer shall have first given written notice to the Company of such failure specifying in reasonable detail the condition(s) that are not satisfied and the basis therefor, and the Company shall have failed to cure such failure within thirty (30) days after receipt of such notice; and provided, further, that the right to terminate pursuant to this Section 8.1(d) shall not be available to Buyer if Buyer is then in material breach of any of its representations, warranties, covenants or agreements hereunder."
The "Outside Date" is defined in SPA § 8.1(b) as December 10, 2024 (six months after the date of the SPA). The Outside Date is not subject to extension under the terms of the SPA.
C. Section 1.1 — Material Adverse Effect Definition
The definition of "Material Adverse Effect" in SPA § 1.1 is central to the analysis of both the bring-down condition under § 7.2(a) and the standalone no-MAE condition under § 7.2(b). The definition provides, in relevant part:
"'Material Adverse Effect' means any event, change, development, occurrence, condition, or effect that, individually or in the aggregate with all other events, changes, developments, occurrences, conditions, or effects, has had or would reasonably be expected to have a material adverse effect on (a) the business, results of operations, financial condition, or assets of the Company, taken as a whole, or (b) the ability of the Sellers to consummate the Transactions contemplated by this Agreement."
The definition contains enumerated carveouts excluding the following categories of events from the MAE analysis:
(i) changes in general economic or political conditions in the United States or any other country or region in which the Company operates;
(ii) changes in conditions generally affecting the biotechnology or pharmaceutical industries in which the Company operates;
(iii) changes in applicable law (including any FDA regulations) or in generally accepted accounting principles ("GAAP"), or the interpretation or enforcement thereof;
(iv) pandemics, epidemics, or disease outbreaks (including COVID-19 and any variants thereof), or any escalation or worsening thereof;
(v) earthquakes, hurricanes, floods, or other natural disasters, acts of war (whether or not declared), armed hostilities, sabotage, terrorism, or any escalation or worsening of any such acts of war, hostilities, sabotage, or terrorism;
(vi) changes in the financial, banking, or securities markets generally (including any disruption thereof or any decline in the price of any security or any market index); and
(vii) the announcement or pendency of the Transactions contemplated by this Agreement, or any actions required to be taken pursuant to this Agreement.
Critically, carveouts (i) through (vi) are subject to a "disproportionate impact" exception. Specifically, the SPA provides:
"provided, however, that with respect to clauses (i) through (vi) above, any such event, change, development, occurrence, condition, or effect may be taken into account in determining whether a Material Adverse Effect has occurred to the extent such event, change, development, occurrence, condition, or effect has a disproportionate adverse impact on the Company relative to other companies of similar size operating in the biotechnology industry."
We note that the MAE definition includes the formulation "has had or would reasonably be expected to have" a material adverse effect. The inclusion of this forward-looking language means that Penterra need not demonstrate that the full adverse consequences of the clinical hold and the Marlowe Asset Management-2 data have already been realized; it is sufficient to show that such consequences "would reasonably be expected" to materialize. This forward-looking component is significant in light of the inherent uncertainty regarding the timeline for resolution of the clinical hold and the future development trajectory of VRD-4187.
IV. Analysis: Impact of the Partial Clinical Hold on Section 7.2(a) — Bring-Down of Representations
The bring-down condition under SPA § 7.2(a) requires that the Sellers' representations and warranties set forth in Article III of the SPA be true and correct as of the Closing Date as though remade on such date. As detailed below, we believe the partial clinical hold and the underlying Marlowe Asset Management-2 clinical data render at least certain of these representations inaccurate as of August 22, 2024, and that such inaccuracies are of sufficient magnitude to constitute a failure of the bring-down condition.
A. Sellers' Regulatory Compliance Representations
The Sellers represented in SPA § 3.14 that the Company "is and has been in compliance in all material respects with all applicable laws, rules, and regulations (including, without limitation, all applicable FDA regulations, including 21 C.F.R. Parts 50, 56, 312, and 314, and all applicable requirements of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ('ICH') guidelines)."
The imposition of a partial clinical hold by the FDA on IND 154832 is a formal regulatory determination by the agency that subjects in the Marlowe Asset Management-2 trial face an "unreasonable and significant risk of illness or injury" as a consequence of the clinical investigation being conducted under the IND. See 21 C.F.R. § 312.42(b)(1). This is the FDA's most direct and consequential form of intervention in the conduct of a clinical trial, short of termination of the IND itself. By its nature, the FDA's decision to impose a clinical hold reflects the agency's judgment that there is a sufficiently serious safety concern to warrant restricting the sponsor's ability to continue the clinical investigation in its current form.
The imposition of the hold raises a direct challenge to the continuing accuracy of the representation that the Company's clinical programs are being conducted in compliance with applicable regulatory requirements. While it is true that the imposition of a clinical hold does not, in and of itself, constitute a finding by the FDA that the sponsor has violated FDA regulations (a clinical hold may be imposed based on emerging safety data even where the sponsor has complied with all applicable procedural requirements), the practical significance of the hold is that the FDA has determined that the clinical program, as currently designed and conducted, presents unacceptable safety risks. At minimum, this raises serious questions about whether the broad representation of regulatory compliance can be maintained as of the date of closing.
Moreover, the analysis should not focus solely on the hold itself in isolation; the underlying clinical data that precipitated the hold is equally, if not more, relevant. The safety signal — a 23.4% rate of Grade ≥3 CRS and seven treatment-related deaths — represents a dramatic departure from the safety profile described in Veridian's IND application and the data available during Penterra's due diligence process. To the extent the Sellers' regulatory compliance representations encompass the adequacy of the Company's safety monitoring, adverse event reporting, and protocol compliance during the conduct of the Marlowe Asset Management-2 trial, the emergence of these data and the subsequent regulatory action call the accuracy of those representations into question.
We note that there is a conceptual distinction between a partial clinical hold and a full clinical hold. A partial hold restricts certain specified aspects of the clinical investigation (in this case, new enrollment and certain ongoing dosing activities), while a full hold would require the complete cessation of all clinical activities under the IND. However, this distinction should not diminish the significance of the hold for purposes of the bring-down analysis. The hold applies to VRD-4187, which is the Company's lead pipeline candidate, its most advanced clinical-stage asset, and the primary strategic asset underlying the $900 million acquisition price. A regulatory action restricting development of this specific asset is material by any reasonable measure, regardless of whether it is characterized as "partial" in regulatory terms.
B. Sellers' Representations Regarding Clinical Trials
The Sellers represented in SPA § 3.15 that "all clinical trials conducted by or on behalf of the Company have been and are being conducted in all material respects in accordance with (i) the applicable protocols therefor (including all amendments thereto), (ii) all applicable requirements of Good Clinical Practice ('GCP') as set forth in 21 C.F.R. Part 312 and the ICH E6 guidelines, and (iii) all other applicable laws and regulations." The representation further stated that "no clinical trial conducted by or on behalf of the Company has been terminated, suspended, or placed on clinical hold by the FDA or any other regulatory authority."
As of August 22, 2024, the second clause of this representation is no longer accurate. VRD-4187 has been placed on a partial clinical hold by the FDA. The representation was accurate as of the signing date of June 10, 2024; it is no longer accurate as of the present date. Under the bring-down standard of SPA § 7.2(a), this representation must be true as of the Closing Date, and it plainly will not be true at any point while the partial clinical hold remains in effect.
With respect to the first clause of the representation — that clinical trials have been conducted in accordance with applicable protocols, GCP, and applicable laws — the DMC's recommendation to suspend enrollment and the FDA's subsequent imposition of the partial clinical hold raise substantial questions about whether the Marlowe Asset Management-2 trial was being conducted safely under the existing protocol (Protocol v3.2). The adverse event data observed in the interim analysis — particularly the 23.4% rate of Grade ≥3 CRS and the seven treatment-related deaths — materially deviate from the safety profile described in Veridian's original IND application, the investigator's brochure, and the information that was made available to Penterra during the due diligence process (as documented in Broadleaf Scientific Consulting's original clinical due diligence assessment prepared during March through May 2024).
The Phase I dose-escalation study (Marlowe Asset Management-1) had reported a Grade ≥3 CRS rate of approximately 8% at the 1.5 mg/kg dose level, with no treatment-related deaths. The Marlowe Asset Management-2 Phase II data reflect an approximately three-fold increase in severe CRS rates and the emergence of a previously unobserved mortality signal. While the emergence of previously unseen safety signals in Phase II trials is not inherently indicative of protocol non-compliance or GCP violations, the magnitude of the safety signal raises questions about the adequacy of the Company's safety monitoring procedures, dose-escalation rationale, and adverse event management protocols during the trial.
C. Sellers' Representations Regarding Absence of Governmental Orders
The Sellers represented in SPA § 3.9 that "there are no outstanding governmental orders (including, without limitation, judgments, injunctions, decrees, stipulations, or awards) against or affecting the Company, its business, or any of its assets."
A partial clinical hold constitutes a governmental order issued by the FDA pursuant to its authority under 21 C.F.R. § 312.42 directing the Company to cease certain clinical activities under IND 154832. The hold is a binding regulatory directive with which the Company must comply. To the extent the representation in § 3.9 is a continuing representation subject to the bring-down standard of § 7.2(a), it is no longer accurate as of August 22, 2024, and will remain inaccurate for as long as the partial clinical hold is in effect.
Veridian may argue that the partial clinical hold is not a "governmental order" within the meaning of the SPA's representation — for example, by characterizing it as a regulatory communication or a provisional administrative action rather than a judicial or quasi-judicial order. We believe this argument is unpersuasive. The SPA's definition of "Governmental Order" in § 1.1, while not specifically enumerating clinical holds, is broadly drafted to include "any order, ruling, decision, verdict, decree, writ, subpoena, mandate, precept, command, directive, consent, approval, award, judgment, injunction, or other similar determination or finding by, before, or under the supervision of any Governmental Authority." The FDA is a "Governmental Authority" under the SPA, and a clinical hold is a binding "directive" or "command" issued by that authority. The plain language of the SPA supports classifying the clinical hold as a "Governmental Order."
D. Materiality Qualifier and MAE Standard
The bring-down condition under § 7.2(a) does not require perfect accuracy of every representation and warranty; rather, it permits inaccuracies that, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. Accordingly, the question is not merely whether certain representations have become inaccurate — it is whether the inaccuracies are of sufficient magnitude to clear the MAE threshold.
We note, however, that certain of the representations at issue may be "fundamental representations" that are not subject to the global MAE qualifier in the bring-down. The SPA should be reviewed carefully on this point. To the extent the regulatory compliance representation (§ 3.14), the clinical trial representation (§ 3.15), and the governmental orders representation (§ 3.9) are included within the definition of "Fundamental Representations" in the SPA (or are independently qualified by their own internal materiality standard), the analysis of whether the MAE threshold has been met may be different for each individual representation.
Setting aside the question of which specific representations are qualified and which are unqualified, we believe there is a strong argument that the inaccuracies described above — considered in the aggregate and in the context of VRD-4187's centrality to the Company's business and to the Transaction — rise to the level of a Material Adverse Effect. VRD-4187 is not a secondary or peripheral asset of the Company; it is the Company's lead clinical candidate, its most advanced asset, and the core of the Company's enterprise value. The Company has no product revenue, no marketed products, and no other pipeline candidates in advanced clinical development. The partial clinical hold on VRD-4187 effectively freezes the development of the Company's core asset for an indeterminate period, fundamentally altering the Company's business prospects.
E. Conclusion on Section 7.2(a)
For the reasons set forth above, we believe the partial clinical hold renders at least certain of the Sellers' representations and warranties inaccurate as of the present date, and that the inaccuracies are of sufficient magnitude to constitute a failure of the bring-down condition under SPA § 7.2(a). In particular:
• The representation regarding the absence of governmental orders (§ 3.9) is directly and unambiguously contradicted by the existence of the FDA partial clinical hold.
• The representation that no clinical trial has been placed on clinical hold (§ 3.15) is directly and unambiguously contradicted by the FDA's action on August 22, 2024.
• The regulatory compliance representation (§ 3.14) is called into serious question by the FDA's determination that subjects in the Marlowe Asset Management-2 trial face an unreasonable and significant risk of illness or injury.
Given that the hold applies to VRD-4187 — the Company's lead and most valuable asset, and the primary strategic rationale for the $900 million acquisition — we believe there is a strong argument that these inaccuracies, individually and in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect on the Company's business, taken as a whole. Accordingly, the bring-down condition under § 7.2(a) is not satisfied and is unlikely to be satisfied prior to the Outside Date absent a lifting of the clinical hold and a material change in the underlying clinical data.
V. Analysis: Impact of the Partial Clinical Hold on Section 7.2(b) — No Material Adverse Effect Condition
A. Framework for Material Adverse Effect Analysis
The condition set forth in SPA § 7.2(b) requires that no Material Adverse Effect shall have occurred since the date of the SPA (June 10, 2024). The MAE analysis under the SPA is governed by Delaware law, as specified in SPA § 10.6.
Delaware case law has established several foundational principles for the analysis of MAE claims, which we summarize here and will develop in substantially greater detail in the companion MAE memorandum:
Durationally Significant Impact. The Delaware Court of Chancery has held that an MAE requires a showing that the adverse event substantially threatens the "overall earnings potential of the target in a commercially reasonable manner" and that the effect is "measured in years, not months." Akorn, Inc. v. Fresenius Kabi AG, 2018 WL 4719347 (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018). In Akorn, the court found an MAE where the target company experienced a persistent and dramatic decline in financial performance attributable to company-specific factors (regulatory non-compliance and loss of market share), distinguishing prior Delaware decisions that had found no MAE on the basis of short-term or cyclical declines.
Substantial Threat to Business as a Whole. The MAE standard requires that the adverse effect be evaluated with respect to the target company's business "taken as a whole." The question is whether the event materially and adversely affects the company's overall enterprise value and long-term earnings potential, not merely a single product or business segment — although where a single product or candidate constitutes the substantial entirety of a company's value (as is the case here), the distinction between the product and the company "taken as a whole" is substantially diminished.
Forward-Looking Component. The SPA's MAE definition includes the formulation "has had or would reasonably be expected to have" a material adverse effect. This forward-looking language means that Penterra need not wait until the full adverse consequences have materialized; it is sufficient to show that such consequences are reasonably expected to occur.
Burden of Proof. The burden of establishing an MAE rests on the party asserting it — in this case, Penterra. While this burden is significant, the Akorn court demonstrated that it is not insurmountable where the facts support a finding of sustained, company-specific deterioration.
B. The Partial Clinical Hold as Evidence of a Material Adverse Effect
The partial clinical hold should not be analyzed as a standalone event disconnected from its underlying causes and consequences. Rather, it must be evaluated in conjunction with the Marlowe Asset Management-2 clinical data — specifically, the severe safety signal and the lack of meaningful efficacy differentiation — that precipitated the hold. It is the totality of these circumstances, not the administrative action of the hold alone, that constitutes the basis for an MAE determination.
The significance of the FDA's action cannot be overstated. The imposition of a clinical hold is an extraordinary regulatory intervention reflecting the agency's determination that subjects in the clinical investigation face an "unreasonable and significant risk of illness or injury." 21 C.F.R. § 312.42(b)(1). The FDA does not impose clinical holds lightly or routinely; they are reserved for circumstances involving serious safety concerns that cannot be adequately addressed through less restrictive means (such as protocol amendments, safety letters to investigators, or modifications to the investigator's brochure). The fact that the FDA determined that a partial clinical hold was warranted here — rather than permitting Veridian to address the safety signal through voluntary protocol modification — reflects the gravity of the safety concerns presented by the Marlowe Asset Management-2 data.
The clinical hold effectively freezes the clinical development pathway for VRD-4187 for an indeterminate period. While the hold remains in effect, Veridian cannot enroll new patients in the Marlowe Asset Management-2 trial and may be restricted in its ability to continue dosing currently enrolled patients. This means that the Company's most advanced and most valuable clinical program is in a state of suspended animation, with no certainty as to when — or whether — meaningful clinical development can resume.
Even if the hold is eventually lifted (which is not assured and, based on historical precedent, could take months or longer), the consequences of the hold and the underlying data will persist. The need for dose modification (from 1.5 mg/kg to 0.75 mg/kg), the imposition of mandatory prophylactic measures (such as tocilizumab pre-treatment), and the potential redesign of the Marlowe Asset Management-2 trial protocol fundamentally alter the clinical development strategy and commercial trajectory of VRD-4187. A dose reduction of this magnitude (50%) is not a minor protocol amendment; it raises fundamental questions about the pharmacokinetics, pharmacodynamics, efficacy, and therapeutic window of the drug candidate at the reduced dose level. There is no assurance that VRD-4187 will demonstrate meaningful efficacy at the 0.75 mg/kg dose level, particularly given that the drug failed to show statistically significant efficacy over standard of care at the higher 1.5 mg/kg dose in the Marlowe Asset Management-2 interim analysis.
VRD-4187 is the core strategic asset underpinning the Transaction. The Company has no product revenue, no marketed products, and no other clinical candidates in advanced development. The Company's entire enterprise value is, for practical purposes, derived from the clinical and commercial potential of VRD-4187 and the VeriTCE platform. The impact of the clinical hold and the underlying data on VRD-4187 is therefore tantamount to an impact on the Company "taken as a whole." Unlike a diversified pharmaceutical company with multiple revenue-generating products and a deep pipeline, where the failure of a single clinical candidate might not constitute an MAE, Veridian's dependence on VRD-4187 means that an adverse development of this magnitude with respect to that candidate necessarily constitutes an adverse development with respect to the Company as a whole.
C. The Clinical Data Underlying the Hold
The Marlowe Asset Management-2 interim analysis data merit independent consideration as evidence of an MAE, separate from the regulatory action of the hold itself. Even if the hold were lifted tomorrow, the clinical data would remain unchanged, and the implications for VRD-4187's development and commercialization prospects would persist.
The key data points are as follows:
(i) Grade ≥3 CRS at 23.4% (Treatment) vs. 4.1% (Control). The approximately 5.7-fold increase in severe CRS in the treatment arm is a safety signal of considerable magnitude. CRS is a known class effect of T-cell engagers, but the rates observed in Marlowe Asset Management-2 substantially exceed those reported for approved or late-stage T-cell engager therapies. By way of comparison, blinatumomab (Blincyto®), the most commercially successful T-cell engager currently on the market, has a Grade ≥3 CRS rate of approximately 2% in its approved indication for acute lymphoblastic leukemia. The 23.4% rate observed with VRD-4187 is approximately an order of magnitude higher, raising serious questions about the drug's therapeutic index and its suitability for use in the community oncology setting (as opposed to specialized academic medical centers with intensive care capabilities).
(ii) Treatment-Related Deaths at 3.6% (Treatment) vs. 0.5% (Control). The seven treatment-related deaths in the VRD-4187 arm represent a clinically meaningful and statistically significant mortality signal. In the context of a second-line SCLC therapy, where patients already face a poor prognosis, the acceptable threshold for treatment-related mortality is necessarily low — particularly where the drug does not offer a clear efficacy advantage over existing treatment options. A treatment-related mortality rate of 3.6% in a Phase II trial is likely to be viewed by the FDA and by the clinical community as unacceptable in the absence of a compelling efficacy benefit.
(iii) ORR of 31.4% (Treatment) vs. 28.9% (Control); p = 0.58. The absence of a statistically significant efficacy advantage is, in many respects, as significant as the safety signal. Even if the safety concerns could theoretically be mitigated through dose modification, prophylaxis, or other risk mitigation measures, the fundamental question remains: does VRD-4187 offer a clinically meaningful benefit to patients that justifies the risks associated with its use? The interim data suggest that the answer to this question, at the 1.5 mg/kg dose level, is no. The ORR difference of 2.5 percentage points is well within the range of statistical noise, and the p-value of 0.58 indicates no statistically discernible treatment effect. This raises the prospect that VRD-4187, even in the absence of safety concerns, may not be an effective drug in this patient population.
The Broadleaf Scientific Consulting supplemental assessment dated August 19, 2024, which was prepared by Dr. Raymond Kapoor specifically for Penterra's use in evaluating these developments, confirmed the severity of these findings. Dr. Kapoor's assessment stated, in relevant part, that "the combination of a clinically unacceptable CRS rate, a significant treatment-related mortality signal, and the absence of a meaningful efficacy advantage over standard of care raises fundamental questions about the future development and commercial viability of VRD-4187" and that "the risk-benefit profile of VRD-4187, as reflected in the Marlowe Asset Management-2 interim data, is substantially worse than the profile presented during the diligence process and is unlikely to support regulatory approval in its current form."
D. Applicability of MAE Carveouts
A critical element of the MAE analysis is whether any of the enumerated carveouts in the MAE definition applies to exclude the clinical hold and underlying data from consideration. Based on our preliminary assessment, none of the carveouts applies to the circumstances at hand.
(i) General Economic or Political Conditions (Carveout (i)). The clinical hold and the Marlowe Asset Management-2 data are not attributable to general economic or political conditions. They are the direct product of a specific clinical trial conducted by Veridian involving Veridian's proprietary drug candidate. This carveout is plainly inapplicable.
(ii) Conditions Generally Affecting the Biotech/Pharma Industries (Carveout (ii)). This carveout is the one most likely to be invoked by Veridian. Veridian might argue that clinical trial failures and adverse safety findings are inherent risks of the biotechnology industry and therefore constitute "conditions generally affecting" the industry. We believe this argument fails for two independent reasons. First, the carveout is intended to exclude broad, industry-wide trends or conditions (such as a general tightening of FDA regulatory standards, industry-wide pricing pressures, or systemic changes in the reimbursement landscape), not company-specific clinical trial results. The clinical hold was imposed on VRD-4187 specifically, not on T-cell engagers generally or on immuno-oncology agents as a class. Second, even if the carveout could theoretically apply, the disproportionate impact exception would be triggered: the clinical hold and safety data disproportionately affect Veridian relative to other comparably situated biotechnology companies, given that VRD-4187 is Veridian's sole advanced clinical candidate and the overwhelming source of its enterprise value.
(iii) Changes in Law or GAAP (Carveout (iii)). The clinical hold is not attributable to a change in law or in accounting standards. The FDA's authority to impose clinical holds under 21 C.F.R. § 312.42 existed at the time the SPA was executed. This carveout is inapplicable.
(iv) Pandemics (Carveout (iv)). The pandemic carveout, which specifically references COVID-19 and similar public health emergencies, is plainly inapplicable to a clinical hold arising from company-specific adverse event data in a clinical trial.
(v) Natural Disasters, Acts of War, or Terrorism (Carveout (v)). Inapplicable.
(vi) Changes in Financial Markets Generally (Carveout (vi)). Inapplicable.
(vii) Announcement or Pendency of the Transaction (Carveout (vii)). There is no evidence or argument that the clinical hold or the Marlowe Asset Management-2 data are attributable to the announcement or pendency of the Transaction.
In summary, the clinical hold and the underlying safety and efficacy data are company-specific events arising from Veridian's proprietary clinical program, and no carveout applies to exclude them from the MAE analysis. A more detailed carveout-by-carveout analysis, including the disproportionate impact exception, will be provided in the companion MAE memorandum.
E. Durational Significance
As noted above, Delaware law requires that an MAE be "durationally significant" — that is, the adverse effect must threaten the target's earnings potential over a period measured in years, not months. We believe the partial clinical hold and the underlying clinical data satisfy this standard.
The partial clinical hold introduces significant and, at this juncture, essentially unquantifiable uncertainty regarding the timeline for further clinical development of VRD-4187. Based on publicly available FDA data and historical precedent, partial clinical holds in oncology programs can take several months to over a year to resolve, depending on the nature and severity of the underlying safety concern and the scope of the sponsor's response. Resolution typically requires the sponsor to submit a complete response to the FDA's clinical hold letter, which may include additional preclinical data, revised protocols, risk evaluation and mitigation strategies ("REMS"), and/or safety monitoring plans. The FDA then has 30 days to respond to the sponsor's submission. In practice, the iterative process of submission, FDA review, and follow-up requests often extends the timeline well beyond the initial 30-day window.
Even in the most optimistic scenario — where Veridian submits a comprehensive response within 30 days of the hold and the FDA lifts the hold promptly thereafter — the combination of required protocol modifications would introduce substantial delays to the clinical program:
• A dose reduction from 1.5 mg/kg to 0.75 mg/kg is not a minor modification. The FDA may require Veridian to conduct additional Phase I dose-finding studies at the 0.75 mg/kg dose level to establish the pharmacokinetic and pharmacodynamic profile, maximum tolerated dose, and preliminary safety and efficacy at the reduced dose before permitting resumption of Phase II enrollment. This alone could add 6–12 months to the development timeline.
• The introduction of mandatory tocilizumab prophylaxis will require protocol amendments, IRB approvals at all 42 clinical sites, revised informed consent documents, and potentially updated investigator training — all of which take time.
• Even if Phase II enrollment resumes at the reduced dose, the trial may need to be partially or entirely re-enrolled, as the data generated at the 1.5 mg/kg dose level may not be poolable with data generated at the 0.75 mg/kg dose level for purposes of the efficacy analysis. This could add another 12–18 months of enrollment and follow-up.
• The cumulative effect of these delays would push back any potential NDA filing and FDA approval of VRD-4187 by at least two to three years relative to the pre-hold development timeline, and likely longer.
These delays directly impact the long-term earnings potential and enterprise value of Veridian. The $900 million purchase price was predicated on a development and commercialization timeline that assumed continued enrollment in Marlowe Asset Management-2 and a potential NDA submission within approximately 24–30 months of closing. A delay of two to three years or more fundamentally alters the net present value of VRD-4187's commercial potential, particularly in light of the competitive landscape for SCLC therapies and the risk that alternative treatments may reach the market during the delay period.
Furthermore, there is a meaningful probability that VRD-4187 will never reach commercialization. The combination of a severe safety signal and the absence of a meaningful efficacy advantage raises the prospect that VRD-4187's clinical development may be abandoned entirely, even if the hold is lifted. If VRD-4187 cannot demonstrate efficacy at the reduced dose level, or if the safety concerns persist even with prophylaxis and dose reduction, the program may become unviable. This is not a speculative risk; it is a reasonable inference from the available data.
F. Conclusion on Section 7.2(b)
In our assessment, the partial clinical hold on VRD-4187, considered together with the underlying Marlowe Asset Management-2 safety and efficacy data, provides a substantial basis for Penterra to assert that a Material Adverse Effect has occurred or would reasonably be expected to occur within the meaning of SPA § 1.1. The condition set forth in SPA § 7.2(b) is not satisfied, and — given the severity and durational significance of the developments described herein — there is a strong argument that it is not capable of being satisfied prior to the Outside Date.
The adverse developments at issue are company-specific, directly affect the Company's core and essentially sole value-generating asset, and are durationally significant in their impact on the Company's business prospects. None of the enumerated MAE carveouts applies, and the disproportionate impact exception would defeat any attempt to invoke the industry-conditions carveout. This conclusion will be further developed and supported by detailed case law analysis in the comprehensive MAE memorandum currently in preparation.
VI. Analysis: Impact on Section 7.2(c) — Covenant Compliance
A. Operating Covenants Under Section 5.1
SPA § 5.1 requires Veridian, during the period between signing and closing, to conduct its business in the ordinary course consistent with past practice and to use commercially reasonable efforts to preserve its business organization, relationships, and assets. These operating covenants are designed to ensure that the Company delivered to the Buyer at closing is substantially the same company that the Buyer agreed to acquire at signing.
The imposition of a partial clinical hold is a regulatory action taken by the FDA, not a voluntary action by Veridian. Accordingly, the hold itself is not directly attributable to a volitional breach of the operating covenants by the Company. However, the analysis does not end there. The question is whether the underlying clinical conduct that precipitated the hold — and, in particular, whether any failure by Veridian to manage, monitor, or escalate the emerging safety signal during the conduct of the Marlowe Asset Management-2 trial in the period between signing and the hold — constitutes a failure to conduct business in the ordinary course or to use commercially reasonable efforts to preserve the Company's business.
For example, if evidence emerges that Veridian was aware of accumulating adverse event data prior to the DMC's formal interim analysis and failed to take appropriate action (such as implementing dose modifications, strengthening safety monitoring protocols, or reporting safety signals to the FDA), such conduct could constitute a breach of the obligation to operate in the ordinary course and preserve the business. Similarly, if Veridian's clinical operations team failed to adhere to standard pharmacovigilance practices or delayed the filing of required safety reports, such conduct could independently constitute a breach.
We note that the factual investigation necessary to assess these questions is ongoing. Calderwood & Harkness will work with Broadleaf Scientific Consulting to analyze the timeline of adverse event reporting, the Company's pharmacovigilance practices during the relevant period, and the adequacy of the Company's internal safety review processes. This analysis may also inform potential claims related to the accuracy of the Sellers' regulatory compliance representations.
B. Notification Obligations Under Section 5.1(b)
SPA § 5.1(b) requires Veridian to promptly notify Penterra of certain specified events occurring between signing and closing, including "any material adverse development relating to the Company's business, operations, assets, properties, financial condition, or prospects." The notification obligation is intended to ensure that the Buyer is kept informed of significant developments that could affect the value of the transaction or the satisfaction of closing conditions.
The DMC conducted its interim analysis on August 14, 2024. Penterra received notice of the DMC findings from Veridian on August 16, 2024 — two calendar days later. The FDA partial clinical hold was imposed on August 22, 2024, and Penterra was notified on the same date.
Whether the two-day lag between the DMC meeting and Veridian's notification to Penterra constitutes a failure to provide "prompt" notice under § 5.1(b) is a factual question that depends on the circumstances. On the one hand, a two-day delay may be defensible if Veridian's management and clinical team needed time to review and assess the DMC's findings before communicating them externally. On the other hand, given the severity of the safety signal — seven treatment-related deaths and a Grade ≥3 CRS rate of 23.4% — there is an argument that Penterra should have been notified immediately upon Veridian's receipt of t